CV Therapeutics Earnings Overshadows Takeover Spec

Print Email

Posted by Thomas Catino

Ant&Sons

Shares of CV Therapeutics Inc. (CVTX) are slumping, down $.60, or 5.52%, to $10.26 on moderate volume. It’s been a volatile ride for the stock that is continuing this morning after the company posted…continued